Ovid Therapeutics Inc. (OVID)
Data as of , from SEC Form 4 filings.
See up to 3 months of OVID. The 7-day demo opens the 1M and 3M ranges and puts OVID on your watchlist.
Start 7-day demoLatest OVID insider trades
Margaret A. Alexander - OfficerOpen-market sale$17K- Jeffrey A. Rona - OfficerOpen-market sale$12K
- Charles Ross Carter
About Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
- NEW YORK, NY
- 23
- 2017
- XNAS
OVID Form 4 activity by transaction type, last 90 days
No Form 4 activity for OVID in the last 90 days.
OVID insider transactions (Form 4)
2218 Form 4 filings on record, the earliest from Dec 16, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Charles Ross Carter - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 footnote F2 | - | |
| ||||||
 Anna Greka | Grant or award | Stock Option (right to buy) | 130,000 | $0.00 | - | |
| Stelios Papadopoulos | Grant or award | Common Stock | 17,578 | $2.56 | $45K | |
| Bart Friedman | Grant or award | Common Stock | 8,789 | $2.56 | $22K | |
 Kevin Joseph Fitzgerald | Grant or award | Common Stock | 17,578 | $2.56 | $45K | |
 Jeremy M. Levin - Officer | Option exercise | Common Stock | 47,333 | $1.40 | $66K | |
| Jeremy M. Levin - Officer | Option exercise | Series A Warrant (right to buy) | 47,333 | $0.00 | - | |
| Margaret A. Alexander - Officer | Open-market sale | Common Stock | 11,656 footnote F1 | $1.45 footnote F2 | $17K | |
| Margaret A. Alexander - Officer | Grant or award | Employee Stock Option (Right to Buy) | 1,435,000 | $0.00 | - | |
| ||||||
| Stelios Papadopoulos | Grant or award | Employee Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Jeremy M. Levin | Grant or award | Employee Stock Option (Right to Buy) | 957,000 | $0.00 | - | |
| Kevin Joseph Fitzgerald | Grant or award | Employee Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Bart Friedman | Grant or award | Employee Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Barbara Gayle Duncan | Grant or award | Employee Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Karen Bernstein | Grant or award | Employee Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Jeffrey A. Rona - Officer | Open-market sale | Common Stock | 8,541 footnote F1 | $1.45 footnote F2 | $12K | |
| Jeffrey A. Rona - Officer | Grant or award | Common Stock | 68,125 footnote F4 | $0.00 footnote F5 | - | |
| Jeffrey A. Rona - Officer | Grant or award | Employee Stock Option (Right to Buy) | 408,750 | $0.00 | - | |
| ||||||
| Kevin Joseph Fitzgerald | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Karen Bernstein | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Bart Friedman | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Barbara Gayle Duncan | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
Recent OVID Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Jeffrey A. Rona | Affiliated Stockholder | 325,000 | $910K | View on EDGAR | |
| Jeffrey A. Rona | Affiliated Stockholder | 150,000 |
OVID insider trading FAQ
What is the latest insider trade for OVID?
Ovid Therapeutics Inc. (OVID) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-08. The full record for OVID runs to 18 Form 4 filings, the earliest from 2024-12-16. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying OVID stock?
No insider purchases of OVID were filed in the last 90 days.
How many insiders are selling OVID stock?
No insider sales of OVID were filed in the last 90 days. 2 sales are on record for this company.
Where can I see OVID SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects OVID Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Charles Ross Carter view on EDGAR
- - Anna Greka view on EDGAR
- - Stelios Papadopoulos view on EDGAR
- - Bart Friedman view on EDGAR
- - Kevin Joseph Fitzgerald view on EDGAR
- - Jeremy M. Levin view on EDGAR
- - Margaret A. Alexander view on EDGAR
- - Stelios Papadopoulos view on EDGAR
- - Jeremy M. Levin view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where OVID's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow OVID with a 7-day demo
- OVID on your watchlist
- Every OVID Form 4 filing on record
- Up to 3 months of OVID price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
